Pfizer’s Growth drivers
Pfizer’s (PFE) business is classified into two business segments—the Innovative Health segment and Essential Health segment. The products that are expected to contribute towards Pfizer’s revenue growth include Eliquis, Sulperazon, Lipitor, Chantix/Champix, Lyrica IH, Xalkori, Xeljanz, Celebrex, Medrol, and Xtandi.
The above chart compares the revenues for Pfizer’s key growth contributors in the past few quarters.
Positive growth contributors
The following products contribute to Pfizer’s positive growth:
- Lurica, one of the blockbuster drugs from Pfizer’s portfolio, is expected to report revenue growth during 4Q17. The growth is expected to be driven by increased US sales and partially offset by lower international sales.
- Ibrance, a blockbuster drug that treats advanced breast cancer, is expected to report growth in 4Q17. The growth will likely be driven by strong uptake of the drug in US markets and revenue growth from international markets.
- Lipitor is another blockbuster drug from Pfizer. Lipitor’s revenues are expected to increase during 4Q17 due to strong sales in US and international markets.
- Xeljanz, a blockbuster drug, is expected to report revenue growth during 4Q17. The revenue growth is expected to be driven by strong sales in US and international markets.
- Chantix/Champix, a drug for reducing the urge to smoke, is expected to report growth in 4Q17. The growth is expected due to strong uptake of the drug in US markets and revenue growth in international markets.
- Xalkori is expected to report an increase in its 4Q17 revenues due to strong sales from international markets. Its revenues could be partially offset by lower sales in US markets.
- Sulperazon is expected to report revenue growth in 4Q17 due to strong demand for the drug in international markets.
- Celebrex is expected to report growth in US sales. The growth will likely be offset by lower sales in international markets.
Wall Street analysts expect Pfizer’s (PFE) top line to increase ~0.7% to ~$13.72 billion in 4Q17. The EPS is expected to increase to $0.56 for 4Q17.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.